Regentis Biomaterials Ltd.RGNT
Price (close)
$2.04
Market cap
$14.3M
P/E
—
Revenue (FY)
—
Net income
-$13.6M
Dividend yield
—
1-year total return
—
Net margin
—
Revenue growth
—
Debt / equity
0.25x
What Regentis Biomaterials Ltd. does.
Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health
and enhance quality of life of patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on
degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a unique hydrogel
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$4.1M | $4.8M | -$13.6M |
More on RGNT.
- Regentis Biomaterials Ltd. summary
- Regentis Biomaterials Ltd. financial statements
- Regentis Biomaterials Ltd. key metrics
- Regentis Biomaterials Ltd. health scores and style box
- Regentis Biomaterials Ltd. earnings
- Regentis Biomaterials Ltd. dividends
- Regentis Biomaterials Ltd. valuation
- Regentis Biomaterials Ltd. ownership and insiders
- Regentis Biomaterials Ltd. peers
Figures from Regentis Biomaterials Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.